La cadena de opciones muestra datos clave de las opciones de acciones de Zymeworks a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Zymeworks..

Zymeworks (NASDAQ:ZYME) Bolsa, Cadena de Opciones

Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks Inc

Gaming company Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) could highlight user growth and better monetization efforts when the company reports fourth-quarter financial results before <a href="https://www.benzinga.com/earnings">market open Thursday.</a>
Earnings Estimates: Analysts expect Roblox to report fourth-quarter revenue of $1.35 billion, up from $1.13 billion in last year's fourth quarter according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in two straight quarters and seven of the past 10 quarters overall.
Analysts expect Roblox to report a loss of 45 cents per share in the fourth quarter, an improvement from a loss of 52 cents per share in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in five straight quarters and six of the past 10 quarters overall.
Read Also: <a href="https://www.benzinga.com/25/01/43325891/backed-by-youtube-king-mrbeast-group-of-american-investors-including-roblox-ceo-lock-in-over-20-billion-for-tiktok-takeover-but-they-have-not-heard-back-directly-from-bytedance">MrBeast And Group Of Investors, Including Roblox CEO, Lock In Over $20 Billion For TikTok Takeover</a>
Key Items to Watch: The company saw strong growth in bookings, users and average booking per user in the third quarter. Those items will be closely watched by investors and analysts again.
Roblox <a href="https://www.benzinga.com/news/earnings/24/10/41654520/roblox-q3-earnings-bookings-jump-34-user-base-hits-89-million-raises-annual-outlook">ended the third quarter</a> with a user base of 89 million as it puts an emphasis on keeping users engaged on the platform and also working on new initiatives to get older users to remain.
Analysts and investors will be closely watching to see if Roblox shares 2025 guidance for key metrics including bookings, revenue and earnings per share.
With quarterly losses, analysts and investors may look for any commentary on how close the gaming company is to profitability for its long-term sustainability.
Here are recent <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">analyst ratings on Roblox</a> and their price targets:
<ul>
<li>Citigroup: Maintained Buy rating, raised price target from $63 to $82</li>
<li>Piper Sandler: Reiterated Overweight rating, raised price target from $65 to $72</li>
<li>Roth MKM: Maintained Neutral rating, raised price target from $54 to $70</li>
<li>Wells Fargo: Maintained Overweight rating, raised price target from $58 to $76</li>
</ul>
 RBLX Price Action: Heading into the quarterly results, Roblox stock has momentum with shares hitting new 52-week highs of $75.74 on Wednesday. This marked the highest share price for Roblox since January 2022. The stock has traded between $29.55 and $75.74 over the past 52 weeks and shares are up 92% over the past year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/01/43017547/hindenburg-research-is-closing-up-shop-we-shook-some-empires-that-we-felt-needed-shaking">Hindenburg Research Is Closing Up Shop: &#8216;We Shook Some Empires That We Felt Needed Shaking&#8217;</a></li>
</ul>
Photo: Shutterstock

Entertainment

Gaming

Previews

Analyst Ratings

Trading Ideas

RBLX

Roblox Q4 Earnings Preview: Can Gaming Company Beat Analyst Estimates With Shares At Three-Year Highs?

Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) has outperformed the market over the past 15 years by 2.4% on an annualized basis producing an average annual return of 14.55%. Currently, Brookfield has a market capitalization of $89.92 billion. 
Buying $100 In BN: If an investor had bought $100 of BN stock 15 years ago, it would be worth $780.28 today based on a price of $59.61 for BN at the time of writing.
<h3>Brookfield's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738798333_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

$100 Invested In Brookfield 15 Years Ago Would Be Worth This Much Today

Billionaire investor <a href="https://www.benzinga.com/startups/25/01/43084861/mark-cubans-29-million-shark-tank-portfolio-from-200k-in-dude-wipes-to-200m-for-beatbox-beverages-im-killing-it">Mark Cuban</a> recently floated an interesting idea on X. He's thinking about launching his own meme coin, but with a twist. Unlike Donald Trump's $TRUMP token, which made waves in the crypto world, Cuban wants all the proceeds from his token sales to go straight to the U.S. Treasury to help tackle the national debt.
Cuban <a href="https://x.com/mcuban/status/1881445569727758392">said on X</a>: &#8220;If meme coins are the way, maybe I'll issue one. With a twist. Same terms as $TRUMP. 20% float. Same release schedule. One difference. All the revenue from the sale of the coins go to the U.S. Treasury. The wallet address will be published so everyone can track it. If you want to gamble, gamble. But at least use it to make a dent in the U.S. Debt. You in?&#8221;
Don't Miss:
<ul>
<li>Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
To put things into perspective, the U.S. national debt is sitting at a staggering $36.22 trillion, according to the U.S. Treasury. Naturally, Cuban's post blew up, racking up over 60,000 likes and sparking all kinds of reactions.&nbsp;
Some people were quick to call him out, reminding him that he had previously dismissed meme coins as &#8220;shit coins.&#8221; One user, &#8220;Injective AI Intern,&#8221; pointed out the contradiction, and Cuban clapped back, saying, &#8220;Just making the point. If it's a grift, make it a grift to benefit all Americans.&#8221;
Not everyone was against the idea, though. Journalist Brian Krassenstein chimed in, suggesting that Cuban could split the funds—half to the Treasury, half to help lower prescription drug prices.&nbsp;
Trending: According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions">Join the first company to bring blockchain payments to Salesforce early with just $100.</a>
Cuban wasn't on board with that, saying he didn't want to pick favorites and that paying down the national debt was the best way to create broad benefits.
Now, Cuban and Trump have a bit of a history. Cuban has been one of Trump's biggest critics, but at the same time, he's clearly paying attention to the financial success of the $TRUMP meme coin.&nbsp;
That token skyrocketed 1,000% in just two days, peaking at $71 before cooling off to about $26.40 by Jan. 27—still a hefty 300% jump from its launch.
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</a>
But not everyone is thrilled about the rise of political meme coins. Ethereum co-founder Vitalik Buterin has raised red flags, calling them a &#8220;perfect bribery vehicle.&#8221; His concern? Politicians could profit without anyone actually handing them money.&nbsp;
&#8220;If a politician issues a coin, you don't even need to send them any coins to give them money,&#8221; Buterin said. &#8220;Instead, you just buy and hold the coin, and this increases the value of their holdings passively.&#8221; Basically, it's a sneaky way for financial influence to creep into politics.
Of course, not everyone sees it that way. White House AI and<a href="https://www.benzinga.com/24/11/42009965/vaneck-ceo-boldly-predicts-bitcoin-at-300k-per-coin-reaching-half-of-golds-market-cap-in-the-face-of-growing-demand"> crypto</a> advisor David Sacks compared meme coins with collectibles—think baseball cards or stamps. <a href="https://www.youtube.com/watch?v=_zOqyntqzOI">In an interview with Fox Business</a>, he said people aren't necessarily buying these tokens for financial gain but as a way to support or commemorate a political movement.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</a></li>
</ul>

Startups

Mark Cuban Mocks Meme Coins But Pitches One To Cut U.S. Debt: 'If It's A Grift, Make It A Grift To Benefit All Americans'

Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has outperformed the market over the past 20 years by 9.24% on an annualized basis producing an average annual return of 17.63%. Currently, Illumina has a market capitalization of $19.82 billion. 
Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,447.88 today based on a price of $125.00 for ILMN at the time of writing.
<h3>Illumina's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738797309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ILMN

Here's How Much $100 Invested In Illumina 20 Years Ago Would Be Worth Today

DA Davidson analyst Tom White maintains Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) with a Buy and raises the price target from $53 to $57.

Price Target

CRTO

DA Davidson Maintains Buy on Criteo, Raises Price Target to $57

Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) sees Q1 sales of $158.000 million-167.000 million vs $183.95 million estimate.

Guidance

SIMO

Silicon Motion Technology Sees Q1 Sales $158.000M-167.000M vs $183.95M Est

DA Davidson analyst Linda Bolton Weiser maintains Mattel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) with a Buy and raises the price target from $27 to $30.

DA Davidson Maintains Buy on Mattel, Raises Price Target to $30

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.77 by 18.18 percent. This is a 2.15 percent decrease over earnings of $0.93 per share from the same period last year. The company reported quarterly sales of $191.16 million which missed the analyst consensus estimate of $195.78 million by 2.36 percent. This is a 5.54 percent decrease over sales of $202.38 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Silicon Motion Technology Q4 Adj EPS $0.91 Beats $0.77 Estimate, Sales $191.16M Miss $195.78M Estimate

Buybacks

Silicon Motion Plans New $50M Share Repurchase Program

Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) has outperformed the market over the past 5 years by 7.75% on an annualized basis producing an average annual return of 20.25%. Currently, Fluor has a market capitalization of $8.19 billion. 
Buying $100 In FLR: If an investor had bought $100 of FLR stock 5 years ago, it would be worth $261.90 today based on a price of $47.77 for FLR at the time of writing.
<h3>Fluor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738796409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Fluor 5 Years Ago Would Be Worth Today

"This manuscript provides comprehensive data on the safety and efficacy of Bizengri and demonstrates the meaningful results observed in the eNRGy trial," said&nbsp;Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "We continue to make significant progress across our clinical pipeline of important and new cancer therapeutic candidates, all from our own Biclonics&nbsp;antibody technologies."

MRUS

Merus Says New England Journal Of Medicine Published Results Of Registrational Phase 2 eNRGy Trial For Bizengri

The dividend is payable on April 15, 2025 to common stockholders of record as of March 31, 2025.

Dividends

AvalonBay Communities Boosts Dividend By 2.9% From $1.70 To $1.75 Per Share

Skyworks Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares are trading lower in Wednesday&#8217;s after-hours session after the company reported quarterly financial results and <a href="https://www.benzinga.com/pressreleases/25/02/g43512179/inseego-announces-chairman-of-the-board-transition">announced a CEO transition</a>.
<ul>
<li>Q1 Revenue: $1.068 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.066 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $1.60, versus estimates of $1.57</li>
</ul>
&#8220;Skyworks started the new fiscal year with solid results, growing revenue&nbsp;4%&nbsp;sequentially and surpassing the midpoint of our&nbsp;guidance,&#8221; said Liam Griffin, president and CEO of Skyworks. 
&#8220;We have observed consistent improvement in demand indicators within Broad Markets, while we have successfully supported multiple new product launches in Mobile. Furthermore, we posted another quarter of impressive free cash flow with margins exceeding&nbsp;30%.&#8221;
Skyworks&#8217; board approved a share repurchase program of up to $2 billion through Feb. 3, 2027. The buyback succeeds in its entirety the repurchase program that was approved in 2023. The company also declared a cash dividend of 70 cents per share, payable on March 17 to shareholders of record as of Feb. 24. 
Check This Out: <a href="https://www.benzinga.com/25/02/43509115/qualcomm-q1-earnings-highlights-record-revenue-eps-beat-estimates">Qualcomm Q1 Earnings Highlights: Record Revenue, EPS Beat Estimates, &#8216;Growth Across Our Diversification Initiatives&#8217;</a>
Q2 Outlook: Skyworks expects second-quarter revenue to be between $935 million and $965 million versus estimates of $949.04 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company anticipates second-quarter adjusted earnings of $1.20 per share versus estimates of $1.22 per share. 
&#8220;We anticipate a mid-to-high teens sequential decline in mobile, consistent with historical seasonal patterns. In broad markets, we expect additional sequential and year-over-year growth,&#8221; said Kris Sennesael, senior vice president&nbsp;and CFO of Skyworks.
Leadership Transition: Skyworks announced Griffin will step down as CEO and board member. Philip Brace has been appointed president, CEO and a board member, effective Feb. 17. Griffin will remain with the company for three months to ensure a smooth transition process.
Christine King, who has served as Skyworks&#8217; lead independent director since 2019, has been appointed as chairman of the board.
SWKS Price Action: <a href="http://benzinga.com/quote/swks">Skyworks shares</a> were down 22.69% after hours at $67.32 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Management

After-Hours Center

Movers

SWKS

Skyworks Solutions Shares Are Tumbling After Hours: What's Going On?

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) has outperformed the market over the past 20 years by 3.91% on an annualized basis producing an average annual return of 12.3%. Currently, Alaska Air Gr has a market capitalization of $9.17 billion. 
Buying $1000 In ALK: If an investor had bought $1000 of ALK stock 20 years ago, it would be worth $10,191.84 today based on a price of $74.50 for ALK at the time of writing.
<h3>Alaska Air Gr's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738795512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Alaska Air Gr 20 Years Ago Would Be Worth This Much Today

Sangoma Technologies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/STC#TSX">STC</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $59.10 million which missed the analyst consensus estimate of $63.18 million by 6.46 percent. This is a 5.10 percent decrease over sales of $62.28 million the same period last year.

TSX:STC

Sangoma Technologies Q2 EPS $(0.06) Misses $(0.03) Estimate, Sales $59.10M Miss $63.18M Estimate

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) annnounced its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/n43509453/viking-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corpor">details from the report.&nbsp;</a>
The Details:&nbsp;Viking Therapeutics reported quarterly losses of&nbsp;32 cents&nbsp;per share, which missed the analyst consensus estimate for losses of 28 cents. The company reported losses of&nbsp;25 cents&nbsp;per share in the same period last year.
Viking reported a net loss of&nbsp;$35.4 million in the fourth quarter, compared to a net loss of&nbsp;$24.6 million, in the corresponding period in 2023.
Research and development expenses for the year ended Dec. 31, 2024, were $101.6 million compared to $63.8 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for drug candidates, stock-based compensation and salaries and benefits, partially offset by a decrease in expenses related to clinical studies and preclinical studies.
Read Next:<a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details"> Ford Shares Skid After Q4 Report: Details</a>
&#8220;2024 was an exciting and extremely productive year for Viking,&#8221; stated Brian Lian, Ph.D., CEO of Viking. 
&#8220;During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for the treatment of MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD. Each of these studies successfully achieved their objectives with each in our view demonstrating best-in-class data,&#8221; Lian said. 
VKTX Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Viking Therapeutics shares are down 8.72% after hours at $30.58 on Wednesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43468887/robert-f-kennedy-nomination-advances-to-full-senate-vaccine-stocks-drop">Robert F. Kennedy&#8217;s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop&nbsp;</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Health Care

General

VKTX

Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates

McStarlite is a provider of complex sheet metal aerospace components. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. McStarlite Co. will be reported as part of Standex's Engineering Technologies Group business segment. In calendar year 2024, McStarlite revenue was approximately $33 million with an adjusted EBITDA margin above 20%.&nbsp;

Standex Acquires Privately-Held, California-Based McStarlite For $56.5M Cash

Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) is looking for Q1 Adj EPS of $0.06-0.11 vs $0.42 analyst estimate. sees sales of $70.000 million-73.000 million vs $92.91 million estimate.

Impinj Sees Q1 Adj EPS $0.06-0.11 vs $0.42 Est; Sees Sales $70.000M-73.000M vs $92.91M Est

Gold production in 2025 reflects the following:
<ul>
<li>First production from Skouries in 2026 rather than 2025.</li>
<li>At Kisladag, expected production has been impacted by longer than planned leach cycles and lower grade stacked.</li>
<li>At Olympias, expected production has been impacted by a delay in mill expansion commissioning to 650ktpa, and unscheduled maintenance of the gold concentrate filters.</li>
</ul>
"Our updated 2025 gold production guidance is expected to be between 460,000 and 500,000 ounces. This has been lowered from our prior outlook provided in 2024 to reflect the change in initial production at Skouries from the third quarter of 2025 to the first quarter of 2026. In addition, guidance at both Kisladag and Olympias has been lowered compared to our prior 2025 guidance provided in 2024," the company said.&nbsp;

Eldorado Gold Updates 2025 Gold Production Guidance To 460,000 - 500,000 Ounces; Now Expects First Production At Skourie In Q1 Of 2026 Rather Than 2025

Wells Fargo raised the firm's price target on Zymeworks (ZYME) to $14 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted pr...

Zymeworks price target raised to $14 from $12 at Wells Fargo

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Voya Multi-Manager International Small Cap Fund Q3 2024 Commentary

Zymeworks up after sizable purchase by large shareholder

Zymeworks says it has enough cash to operate through H2 2027

Zymeworks ( ($ZYME) ) has shared an update. Zymeworks has outlined its strategic priorities for 2025 and 2026, including the anticipated initiation...

Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $28.00. The co...

Zymeworks (ZYME) Receives a Buy from Stifel Nicolaus

3 Biotech Stocks With Notable Insider Buying

Zymeworks ( ($ZYME) ) just unveiled an update. Zymeworks Inc. announced its participation in several upcoming investor conferences, including the O...

Zymeworks to Engage Investors at Key Conferences

AUPH

AVDL

BGNE

BLHWF

CEVMF

CEVMY

COGT

CUYTF

CUYTY

FKURF

JAZZ

LEGIF

LGMMY

MEGEF

NVGS

QFIN

RHHBY

SMFRF

SNWAF

TMIUF

ZIZTF

ZYME

Press Releases

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Comments

Zymeworks

Zymeworks (ZYME) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL